ALLK vs. BTAI, PMVP, OPTN, CUE, ORMP, CLSD, ANIX, ETON, IOBT, and QTTB
Should you be buying Allakos stock or one of its competitors? The main competitors of Allakos include BioXcel Therapeutics (BTAI), PMV Pharmaceuticals (PMVP), OptiNose (OPTN), Cue Biopharma (CUE), Oramed Pharmaceuticals (ORMP), Clearside Biomedical (CLSD), Anixa Biosciences (ANIX), Eton Pharmaceuticals (ETON), IO Biotech (IOBT), and Q32 Bio (QTTB). These companies are all part of the "pharmaceutical preparations" industry.
BioXcel Therapeutics (NASDAQ:BTAI) and Allakos (NASDAQ:ALLK) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, media sentiment, earnings, community ranking, valuation, risk and analyst recommendations.
30.7% of BioXcel Therapeutics shares are held by institutional investors. Comparatively, 84.6% of Allakos shares are held by institutional investors. 35.8% of BioXcel Therapeutics shares are held by company insiders. Comparatively, 16.1% of Allakos shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
BioXcel Therapeutics currently has a consensus price target of $16.71, suggesting a potential upside of 699.73%. Allakos has a consensus price target of $1.83, suggesting a potential upside of 52.78%. Given Allakos' stronger consensus rating and higher probable upside, research analysts plainly believe BioXcel Therapeutics is more favorable than Allakos.
BioXcel Therapeutics has a beta of 0.43, indicating that its share price is 57% less volatile than the S&P 500. Comparatively, Allakos has a beta of 0.86, indicating that its share price is 14% less volatile than the S&P 500.
In the previous week, BioXcel Therapeutics had 6 more articles in the media than Allakos. MarketBeat recorded 15 mentions for BioXcel Therapeutics and 9 mentions for Allakos. BioXcel Therapeutics' average media sentiment score of 0.23 beat Allakos' score of 0.06 indicating that Allakos is being referred to more favorably in the news media.
BioXcel Therapeutics received 57 more outperform votes than Allakos when rated by MarketBeat users. Likewise, 67.23% of users gave BioXcel Therapeutics an outperform vote while only 59.34% of users gave Allakos an outperform vote.
BioXcel Therapeutics has higher revenue and earnings than Allakos. Allakos is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks.
Allakos has a net margin of 0.00% compared to Allakos' net margin of -8,715.72%. BioXcel Therapeutics' return on equity of -86.99% beat Allakos' return on equity.
Summary
BioXcel Therapeutics beats Allakos on 10 of the 17 factors compared between the two stocks.
Get Allakos News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALLK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALLK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
